ProCE Banner Activity

CONRAD 138 (ENRICH): Phase I Trial of Continuous or Interrupted 90-Day TFV/LNG Vaginal Ring in Women Without HIV

Slideset Download
Conference Coverage
Both tenofovir and levonorgestrel met concentration targets in a 90-day trial assessing the TFV/LNG vaginal ring vs placebo, supporting further study of the TFV/LNG ring for HIV prevention.

Released: February 06, 2021

Expiration: February 05, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2021 HIV R4P

ProCE Banner